IDEXX Laboratories, Inc. (IDXX) Insider Giovani Twigge Sells 2,000 Shares
IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Giovani Twigge sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total transaction of $312,140.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of IDEXX Laboratories, Inc. (IDXX) opened at $159.30 on Tuesday. The firm has a market cap of $13,518.90, a P/E ratio of 52.19, a P/E/G ratio of 2.34 and a beta of 0.42. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a 1 year low of $113.71 and a 1 year high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the company posted $0.62 earnings per share. research analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in IDXX. BlackRock Inc. increased its holdings in IDEXX Laboratories by 10.5% in the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares during the last quarter. Advisors Capital Management LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $262,000. Cipher Capital LP purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $2,284,000. American Century Companies Inc. boosted its position in IDEXX Laboratories by 131.7% in the 2nd quarter. American Century Companies Inc. now owns 480,978 shares of the company’s stock valued at $77,639,000 after buying an additional 273,398 shares during the period. Finally, Pitcairn Co. boosted its position in IDEXX Laboratories by 21.8% in the 2nd quarter. Pitcairn Co. now owns 6,977 shares of the company’s stock valued at $1,126,000 after buying an additional 1,249 shares during the period. Institutional investors own 86.80% of the company’s stock.
IDXX has been the topic of several research analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research note on Monday, August 21st. Finally, Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price on the stock in a research note on Tuesday, October 24th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. IDEXX Laboratories presently has an average rating of “Hold” and an average target price of $173.67.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.